Literature DB >> 12474542

Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines.

Paul Jackson1, Marc-Oliver Grimm, Elizabeth A Kingsley, Ute Brosius, Toni Antalis, Gina Yardley, Pamela J Russell.   

Abstract

The molecular basis for the loss of KAI1 expression in invasive and metastatic tumors and tumor cell lines is not understood. Recently, identification of a sequence with homology to the consensus p53-binding motif in the promoter of the KAI1 metastasis suppressor gene, has led to a proposal that transcriptional regulation by p53 controls expression of KAI1, and that a dramatic down-regulation of KAI1 mRNA levels in invasive tumors and many tumor cell lines, is directly due to loss of p53 function. We have tested this hypothesis by assessing KAI1 mRNA levels in a series of 22 cell lines derived from bladder and prostate cancers, in which we confirmed the p53 gene sequence and characterized the functional status of the endogenous p53 protein. We anticipated that cell lines expressing p53 capable of transactivation should express high levels of KAI1 mRNA compared with cell lines expressing defective p53, or which were p53-null. KAI1 mRNA levels were determined by northern analysis using a full-length KAI1 cDNA probe, and varied widely between cell lines examined. However, there was no association between these levels and p53 status. Furthermore, transfection of representative cell lines with wild-type p53, or exposure to DNA damaging agents, had no effect on KAI1 mRNA levels. Our data suggest that p53 is not a major factor regulating levels of KAI1 mRNA in bladder and prostate cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12474542     DOI: 10.1016/s1078-1439(01)00175-2

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  8 in total

1.  Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Authors:  Chengfei Liu; Yezi Zhu; Wei Lou; Nagalakshmi Nadiminty; Xinbin Chen; Qinghua Zhou; Xu Bao Shi; Ralph W deVere White; Allen C Gao
Journal:  Prostate       Date:  2012-09-19       Impact factor: 4.104

Review 2.  Dissecting the diverse functions of the metastasis suppressor CD82/KAI1.

Authors:  Yien Che Tsai; Allan M Weissman
Journal:  FEBS Lett       Date:  2011-08-27       Impact factor: 4.124

3.  KAI1 is a potential target for anti-metastasis in pancreatic cancer cells.

Authors:  Jian-Hua Xu; Xiao-Zhong Guo; Li-Nan Ren; Li-Chun Shao; Min-Pei Liu
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

4.  Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo.

Authors:  Kate Vandyke; Melanie Y White; Terry Nguyen-Khuong; Kim Ow; Sharon C-W Luk; Elizabeth A Kingsley; Alexandra Rowe; Shiu-Fun Pang; Bradley J Walsh; Pamela J Russell
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

5.  Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction.

Authors:  Yan Xue; Lei Li; Dong Zhang; Kaijie Wu; Yule Chen; Jin Zeng; Xinyang Wang; Dalin He
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

6.  The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.

Authors:  Vedran Milosavljevic; Yazan Haddad; Miguel Angel Merlos Rodrigo; Amitava Moulick; Hana Polanska; David Hynek; Zbynek Heger; Pavel Kopel; Vojtech Adam
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240

7.  Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.

Authors:  Emuejevoke Olokpa; Sammed N Mandape; Siddharth Pratap; La Monica V Stewart
Journal:  BMC Cancer       Date:  2022-09-29       Impact factor: 4.638

8.  Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.

Authors:  Rayan S Moussa; Zaklina Kovacevic; Des R Richardson
Journal:  Oncotarget       Date:  2015-10-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.